463 related articles for article (PubMed ID: 22160058)
21. Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives.
Malagola M; Papayannidis C; Baccarani M
Ann Hematol; 2016 Apr; 95(5):681-93. PubMed ID: 26891878
[TBL] [Abstract][Full Text] [Related]
22. Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Mathisen MS; O'Brien S; Thomas D; Cortes J; Kantarjian H; Ravandi F
Curr Hematol Malig Rep; 2011 Sep; 6(3):187-94. PubMed ID: 21660654
[TBL] [Abstract][Full Text] [Related]
23. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Akahoshi Y; Nishiwaki S; Mizuta S; Ohashi K; Uchida N; Tanaka M; Fukuda T; Ozawa Y; Takahashi S; Onizuka M; Shiratori S; Nakamae H; Kanda Y; Ichinohe T; Atsuta Y; Kako S;
Cancer Sci; 2019 Oct; 110(10):3255-3266. PubMed ID: 31402561
[TBL] [Abstract][Full Text] [Related]
24. Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial.
Hunger SP; Tran TH; Saha V; Devidas M; Valsecchi MG; Gastier-Foster JM; Cazzaniga G; Reshmi SC; Borowitz MJ; Moorman AV; Heerema NA; Carroll AJ; Martin-Regueira P; Loh ML; Raetz EA; Schultz KR; Slayton WB; Cario G; Schrappe M; Silverman LB; Biondi A
Lancet Haematol; 2023 Jul; 10(7):e510-e520. PubMed ID: 37407142
[TBL] [Abstract][Full Text] [Related]
25. Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules.
Jabbour E; Cortés JE; Kantarjian H
Clin Lymphoma Myeloma; 2008 Mar; 8 Suppl 3():S75-81. PubMed ID: 19254884
[TBL] [Abstract][Full Text] [Related]
26. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
27. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].
Wang J; Huang X; Jiang B; Qin Y; Bao L; Jiang H; Chen H; Jia J; Yang S; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652
[TBL] [Abstract][Full Text] [Related]
28. Establishment of a new Philadelphia chromosome-positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation.
Okabe S; Tauchi T; Ohyashiki K
Exp Hematol; 2010 Sep; 38(9):765-72. PubMed ID: 20471447
[TBL] [Abstract][Full Text] [Related]
29. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
30. Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review.
Tan KW; Zhu YY; Qiu QC; Wang M; Shen HJ; Huang SM; Cao HY; Wan CL; Li YY; Dai HP; Xue SL
Ann Hematol; 2023 Sep; 102(9):2397-2402. PubMed ID: 37103615
[TBL] [Abstract][Full Text] [Related]
31. Hematopoietic stem cell transplant versus chemotherapy plus tyrosine kinase inhibitor in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).
Salami K; Alkayed K; Halalsheh H; Hussein AA; Riziq M; Madanat F
Hematol Oncol Stem Cell Ther; 2013 Mar; 6(1):34-41. PubMed ID: 23664604
[TBL] [Abstract][Full Text] [Related]
32. Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Cerchione C; Locatelli F; Martinelli G
Front Oncol; 2021; 11():632231. PubMed ID: 33842339
[TBL] [Abstract][Full Text] [Related]
33. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB
Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480
[TBL] [Abstract][Full Text] [Related]
34. [Second-generation tyrosine kinase inhibitors combined with allogeneic hematopoietic stem cell transplant for Philadelphia chromosome positive leukemia].
Yu X; Li C; Wu X; Ye L; Liu H; Ma C; Ma J; Gu C; Wu D
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):129-33. PubMed ID: 24606654
[TBL] [Abstract][Full Text] [Related]
35. T-cell-rich HLA-haploidentical hematopoietic stem cell transplantation for relapsed/refractory pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia without posttransplant tyrosine kinase inhibitor therapy.
Sano H; Mochizuki K; Akaihata M; Kobayashi S; Ohto H; Kikuta A
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27781393
[TBL] [Abstract][Full Text] [Related]
36. [Efficacy comparison of sequential treatment with first-line administration of second-generation and first-generation tyrosine kinase inhibitors in patients with Ph
Yang F; Cai WZ; Yang XD; Chen SN; Tang XW; Sun AN; Wu DP; Qian WQ; Qiu HY
Zhonghua Xue Ye Xue Za Zhi; 2018 Feb; 39(2):110-115. PubMed ID: 29562444
[No Abstract] [Full Text] [Related]
37. Therapeutic approach and outcome of children with Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors: An SFCE retrospective study.
Aubert L; Petit A; Bertrand Y; Ray-Lunven AF; Angoso M; Pluchart C; Millot F; Saultier P; Cheikh N; Pellier I; Plantaz D; Sirvent A; Thouvenin-Doublet S; Valduga J; Plat G; Rialland F; Henry C; Esvan M; Gandemer V
Pediatr Blood Cancer; 2022 Feb; 69(2):e29441. PubMed ID: 34854546
[TBL] [Abstract][Full Text] [Related]
38. Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.
Slayton WB; Schultz KR; Kairalla JA; Devidas M; Mi X; Pulsipher MA; Chang BH; Mullighan C; Iacobucci I; Silverman LB; Borowitz MJ; Carroll AJ; Heerema NA; Gastier-Foster JM; Wood BL; Mizrahy SL; Merchant T; Brown VI; Sieger L; Siegel MJ; Raetz EA; Winick NJ; Loh ML; Carroll WL; Hunger SP
J Clin Oncol; 2018 Aug; 36(22):2306-2314. PubMed ID: 29812996
[TBL] [Abstract][Full Text] [Related]
39. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
Yanada M; Takeuchi J; Sugiura I; Akiyama H; Usui N; Yagasaki F; Kobayashi T; Ueda Y; Takeuchi M; Miyawaki S; Maruta A; Emi N; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
J Clin Oncol; 2006 Jan; 24(3):460-6. PubMed ID: 16344315
[TBL] [Abstract][Full Text] [Related]
40. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]